Navigation Links
Cardica Prices Public Offering Of Common Stock
Date:3/15/2013

REDWOOD CITY, Calif., March 15, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced the pricing of an underwritten public offering of 14,251,368 shares of its common stock, offered at a price to the public of $1.05 per share. The gross proceeds to Cardica from this offering are expected to be $14.96 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cardica. The offering is expected to close on or about March 20, 2013, subject to customary closing conditions. Cardica anticipates using the net proceeds from the offering for general corporate purposes, which may include the costs of research and development activities, and general and administrative and manufacturing expenses.

Wedbush PacGrow Life Sciences is acting as sole manager for the offering.

The shares described above are being offered by Cardica pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on February 7, 2011. The preliminary prospectus supplement is available for free by visiting EDGAR on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from the offices of Wedbush Securities Inc., One Bush Street , 17th Floor, San Francisco, CA 94104, Attn: ECM Prospectus Department, by calling 415-274-6819 or by email at vinnie.devone@wedbush.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Cardica 
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. 

Forward-Looking Statements
Statements contained in this press release regarding Cardica's expectations with respect to the completion, timing and size of its public offering are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with market conditions and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that Cardica will be able to complete the public offering on the anticipated terms, or at all. Other risks and uncertainties relating to Cardica are described more fully under the headings "Risk Factors" in Cardica's most recently filed SEC documents, including its Quarterly Report on Form 10-Q for the quarter ended December 31, 2012. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cardica undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Announces Proposed Public Offering of Common Stock
2. Cardica Updates Enrollment Progress In European Clinical Trial
3. Cardica Announces Fiscal 2013 Second Quarter Financial Results
4. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
5. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
6. Cardica Announces Fiscal 2013 First Quarter Financial Results
7. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
8. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
9. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
10. Cardica Announces Fiscal 2012 Third Quarter Financial Results
11. Pharmacyclics, Inc. Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... ... , ... The Jones Agency, a family owned insurance company with offices serving ... charity drive with the Tarrant Area Food Bank in the hopes of alleviating hunger ... need, the Tarrant County Food Bank offers hope and security to the one in ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Miami Dental Specialists ... to their Miami dental office. Beginning in January, Miami Dental Specialists will offer ... Dental Specialists are the first office to be chosen by the dental implant manufacturer, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. (AIS) ... PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans and ... such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to ...
(Date:2/12/2016)... ... ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter ... teens with and without special needs to gather in a safe and supportive environment. Volunteers ... will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, ...
Breaking Medicine News(10 mins):